American Heart Association Clinical Trial Report indicates that Radiofrequency ablation of target heart tissue shows better results than drug therapy in reducing atrial fibrillation.
Cardio
Jail for Cardiologist Who “Egregiously Violated The Trust Of His Patients”
A US doctor charged in an over-stenting scheme was handed an 8-year prison sentence and ordered to pay nearly $600,000 in restitution for defrauding Medicare and other health insurers.
More from TCT2011: Transfemoral, but not transapical TAVR, “economically attractive”
Researchers claim Transapical TAVR is “unattractive from a health economic perspective.” compared with femoral approach.
“Bridging” Stent Patients to Cardiac Surgery
Late breaking clinical trial results from testing of cangrelor, an investigational intravenous antiplatelet, showed patients can be “bridged” from the time that their physicians stop their oral antiplatelet drugs until they undergo cardiac surgery.
Transcatheter Cardiovascular Therapeutics conference 2011: Live link of UK case highlights FDA’s caution on Sapien Aortic Valve PMA.
Update from TCT2011 sourced from an article by Medical Device Daily
InSeal Medical Announces Patients Successfully Treated with Novel Intravascular Large Bore Puncture Closure Device
InSeal Medical Ltd announced at TCT2011 the successful treatment of three patients with its investigational intravascular large bore puncture closure device.
Despite Higher Sales, Atricure 3rd Quarter Loss Increased as Margins Decrease and Operational Costs Climb
Atricure’s Quarterly Earnings Report gives reason for optimism despite increased losses.
St. Jude Medical Expands US Hospital Access to Wireless Fractional Flow Reserve Technology
St Jude’s cooperation agreement with Philips offers more US hospitals access to the market’s only wireless FFR system
Cordis Empira PTCA Catheters get 510(k) approval for Coronary Artery Disease
Cordis Corporation has announced EMPIRA™ and EMPIRA™ NC RX PTCA Dilatation Catheters have received 510(k) regulatory clearance for the treatment of coronary artery disease.
Thermo-Electric Material May Power Battery-free Cardiac Pacemaker
Japanese researchers have developed a material that can generate power after implantation by absorbing light from outside the body. The technology is being applied to the development of a battery-free cardiac pacemaker.
Medtronic Resolute® Drug-Eluting Stent Shows Strong Results, Even in Challenging Diabetes Patients with Coronary Disease
Pooled Data Analyses to Be Presented at TCT 2011 Demonstrate Heart Device’s Consistently Positive Performance Across Multiple Clinical Studies
Edwards Receives FDA Approval to Expand U.S. Clinical Trial of Next-Generation Transcatheter Valve
Already approved in Europe since March 2010, Edwards’ Sapien XT valve now gains further investigational device study arm in USA.
CE Mark for a New Embolic Protection System During TAVI
Claret Medical Announces CE Mark of a New Embolic Protection System to Address Stroke During Transcatheter Aortic Valve Intervention
Edwards Lifesciences Receives FDA Approval for First Catheter-Based Aortic Heart Valve in the U.S.
Edwards Lifesciences gains first U.S. commercial approval for a transcatheter device enabling aortic valve replacement without the need for open-heart surgery.
Longitudinal Compression in Drug-Eluting Stents on the Agenda
Longitudinal Compression of Drug Eluting Stents with resultant potential shrinkage will be reviewed at the Transcatheter Cardiovascular Therapeutics meeting in San Francisco next week
Abbott Receives U.S. FDA Approval for Next-Generation XIENCE PRIME™ Drug Eluting Stent
Following CE Mark approval in 2009, Abbott now gains FDA approval for Xience Prime Drug Eluting Stent